Press Release

Antithrombin Market to Exhibit 4.1% CAGR, Rising Prevalence of Hereditary Antithrombin Deficiency

The rising demand reported in therapeutics segment is prognosticated to catapult it to the fore of the global antithrombin market in terms of application, finds Fortune Business Insights in a new study. The study is titled “Antithrombin Market: Global Market Analysis, Insights, and Forecasts, 2018 – 2026.” According to the study, the global antithrombin market will exhibit a steady CAGR of 4.1% to reach a value of US$ 725.2 Mn by 2026 from US$ 490.4 Mn in 2018.

Browse Complete Report Details https://www.fortunebusinessinsights.com/industry-reports/antithrombin-market-100470

However, the high treatment cost of antithrombin may compel end users to look for cheaper alternatives or supplements. This may hamper the market globally. Again, developing countries in Asia Pacific may directly opt out of adopting antithrombin treatment because of the high price of this treatment. This may pose a challenge for market players, also hampering the overall profit percentage of the market.

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis: Shire, Grifols,CSL Behring,Kedrion Biopharma,Octapharma, LFB USA, Lee Biosolutions, Inc., Scripps Laboratories, Inc.

Increasing Prevalence of Hereditary Antithrombin Deficiency to Boost Market

The rising prevalence of medical conditions such as sepsis, hereditary antithrombin deficiency, disseminated intravascular coagulation (DIC), and extracorporeal membrane oxygenation (ECMO) is creating lucrative growth opportunities for the antithrombin market. Among various application types, the therapeutics segment is anticipated to lead the market with rising number of antithrombin deficiency cases. In 2018, the therapeutics segment accounted for about 95.7% of the market and is likely to continue its dominance in the future as Fortune Business Insights.

Strong Distribution Network Enables SCL Behring, Grifols, and Shire Expand Global Footprint

The global antithrombin market was dominated by three major companies namely SCL Behring, Grifols, and Shire. In 2018, these three companies together accounted for the highest market share among others. They offer the most commonly used human antithrombin based anticoagulants. Besides this, they have a strong distribution network that makes them have the lion’s share.

Asia Pacific Market to Exhibit Fastest Growth, Gaining Momentum from Rising Disposable Incomes

Geographically, the global antithrombin market is anticipated to show the fastest growth in Asia Pacific. In 2018, the antithrombin market was valued at US$ 179.7 Mn from Asia Pacific alone. A major reason behind this growth is the fact that developing nations such as India and China are adopting new treatment procedures and techniques to fight back various diseases. The rise in disposable incomes of people in developing nations and their increasing ability to spend more on advanced healthcare and medical aid will create lucrative growth opportunities for the market in Asia Pacific.

Request Customization of this [email protected]

Surgical Navigation Systems Market Deep Analysis 2019-2026: Medtronic, CAScination AG, Brainlab

Patient Handling Equipment Market by Geography, End-user & Geography – Forecast to 2026

Crop Protection Chemicals (CPC) Market 2019 Research Analysis, Factors, Top Manufacturers, In-depth Study, Product Types, and Regional Demand 2025

Tags

Jesus Rust

Jesus is leading the environment column. He is a very renowned environmentalist and has worked in many projects, some of which are based in faraway lands too. He always encourages environment conservation and sometimes keeps small group talks about the concerns. His writing and editing skills act the cheery on the top of the cake.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close